It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

Two heads are better than one, as the saying goes, and sometimes two instruments, ingeniously recombined, can accomplish feats that neither could have done on its own.

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

Plastic that conducts electricity might sound impossible. But there is a special class of materials known as "electronic ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

The discovery of this hormone paved the way for Ozempic, making the Gila monster an enormously profitable gift to modern ...